# Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

> **NCT05052801** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Amgen** · enrollment: 547 (actual)

## Conditions studied

- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** Bemarituzumab
- **DRUG:** mFOLFOX6
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05052801
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-03-07
- **Primary completion:** 2025-06-20
- **Final completion:** 2026-06-20
- **Target enrollment:** 547 (ACTUAL)
- **Last updated:** 2026-02-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05052801

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05052801, "Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05052801. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*